Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 10:41 am Purchase | 2024-09-30 | 13G | Savara Inc. SVRA | Wellington Management Group LLP | 8,624,012 5.240% | 8,624,012 (New Position) | Filing History |
| 2024-11-06 6:32 pm Purchase | 2024-09-30 | 13G | Savara Inc. SVRA | Farallon Capital Partners, L.P. | 17,762,533 9.990% | 3,435,622 (+23.98%) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Savara Inc. SVRA | BlackRock Inc. BLK | 9,399,087 5.700% | 1,368,473 (+17.04%) | Filing History |
| 2024-08-14 8:45 pm Unchanged | 2024-08-12 | 13D | Savara Inc. SVRA | Growth Equity Opportunities 17, LLC | 24,471,264 14.900% | 0 (Unchanged) | Filing History |
| 2024-07-08 4:32 pm Purchase | 2024-06-30 | 13G | Savara Inc. SVRA | BlackRock Inc. BLK | 8,030,614 4.900% | 769,084 (+10.59%) | Filing History |
| 2024-04-12 5:26 pm Purchase | 2024-04-10 | 13D | Savara Inc. SVRA | Bain Capital Life Sciences Fund II, L.P. | 14,565,457 13.000% | 332,706 (+2.34%) | Filing History |
| 2024-02-14 8:35 pm Sale | 2023-12-31 | 13G | Savara Inc. SVRA | Venrock Healthcare Capital Partners II, L.P. | 3,500,000 2.600% | -2,851,531 (-44.90%) | Filing History |
| 2024-02-14 4:15 pm Sale | 2024-01-24 | 13G | Savara Inc. SVRA | Zambon SpA | 4,680,000 3.460% | -13,540 (-0.29%) | Filing History |
| 2024-02-13 9:38 pm Purchase | 2024-02-13 | 13G | Savara Inc. SVRA | PRUDENTIAL FINANCIAL INC PRU | 9,788,303 7.230% | 9,788,303 (New Position) | Filing History |
| 2024-02-13 9:00 pm Sale | 2023-12-31 | 13G | Savara Inc. SVRA | CAXTON CORP | 353,441 0.300% | -6,543,110 (-94.88%) | Filing History |
| 2024-02-08 1:31 pm Purchase | 2023-12-31 | 13G | Savara Inc. SVRA | Jennison Associates LLC | 8,815,358 6.500% | 8,815,358 (New Position) | Filing History |
| 2024-02-07 08:01 am Purchase | 2023-12-31 | 13G | Savara Inc. SVRA | ADAGE CAPITAL PARTNERS GP L.L.C. | 7,637,930 5.640% | 773,379 (+11.27%) | Filing History |
| 2024-02-01 3:50 pm Purchase | 2023-12-31 | 13G | Savara Inc. SVRA | Farallon Capital Partners, L.P. | 14,326,911 9.990% | 14,326,911 (New Position) | Filing History |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | Savara Inc. SVRA | BlackRock Inc. BLK | 7,261,530 5.400% | 4,132,550 (+132.07%) | Filing History |
| 2023-07-26 4:57 pm Purchase | 2023-07-17 | 13D | Savara Inc. SVRA | Growth Equity Opportunities 17, LLC | 24,471,264 18.100% | 333,333 (+1.38%) | Filing History |
| 2023-07-25 4:17 pm Purchase | 2023-07-17 | 13G | Savara Inc. SVRA | TCG Crossover GP I, LLC | 10,000,000 7.400% | 10,000,000 (New Position) | Filing History |
| 2023-07-19 4:30 pm Purchase | 2023-07-17 | 13D | Savara Inc. SVRA | Bain Capital Life Sciences Fund II, L.P. | 14,232,751 13.000% | 2,610,153 (+22.46%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Savara Inc. SVRA | Venrock Healthcare Capital Partners II, L.P. | 6,351,531 5.600% | 6,351,531 (New Position) | Filing History |
| 2022-02-14 3:52 pm Unchanged | 2021-12-31 | 13G | Savara Inc. SVRA | CAXTON CORP | 6,896,551 6.100% | 0 (Unchanged) | Filing History |
| 2022-02-14 2:15 pm Unchanged | 2020-12-31 | 13G | Savara Inc. SVRA | EcoR1 Capital, LLC | 3,040,540 5.300% | 0 (Unchanged) | Filing History |